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Abstract
Introduction
Classical epidemiology has established the incremental 
contribution of the high-density lipoprotein cholesterol 
(HDL-C) measure in the assessment of atherosclerotic 
cardiovascular disease (CVD) risk, yet, genetic epidemiology 
does not support a causal relationship between HDL-C 
and the future risk of myocardial infarction. Therapeutic 
interventions directed toward cholesterol loading of the 
HDL particle have been based on epidemiological studies 
that have established HDL cholesterol as a biomarker of 
atherosclerotic CVD risk. The reference range of HDL-C is 
40-50 mg/dL in men and 50-60 mg/dL in women. However, 
therapeutic interventions such as niacin, cholesterylester 
transfer protein (CETP) inhibitors increase HDL-C in 
patients treated with statins, but have repeatedly failed to 
reduce CVD events.(1) Clinical trials with pharmacological 
therapies that increase the cholesterol content of HDL 
particles have failed to establish this convenient metric as 
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R E V I E W  A R T I C L E
BACKGROUND: The strong inverse association of plasma levels of high-density lipoprotein cholesterol (HDL-C)  with coronary heart disease 
(CHD) found in human epidemiological studies led to the 
development of the ‘HDL-C hypothesis’, which posits that 
intervention to raise HDL-C will result in reduced risk of 
CHD. However, recent evidence has raised doubts about the 
hypotheses that elevating HDL-C is necessarily therapeutic. 
Genetic  variations  that  associate  with  altered  HDL-C  do 
not strongly associate with altered cardiovascular disease 
risk. 
CONTeNT: HDL-mediated cholesterol efflux from 
macrophage foam cells or measurements of the flux of 
cholesterol from macrophages to the liver and feces seem 
to correlate better with atherosclerotic burden than with 
HDL-C levels. Thus, it may be time to modify the HDL-C 
hypothesis to the ‘HDL flux hypothesis’, where intervention 
to promote cholesterol efflux and reverse cholesterol 
transport will reduce CHD risk, regardless of whether it 
affects plasma HDL-C levels. A deeper understanding of the 
complex biology of HDL metabolism and its relationship 
to reverse cholesterol transport and atherothrombotic events 
is urgently needed. This might lead to biomarkers of HDL 
flux and functionality that are more informative than simple 
measurements of HDL-C levels.
SUmmARy:  It is now clear from recent clinical trial and 
genetic studies that some approaches to raising HDL-C 
levels may have no effect on CHD. This suggests the need 
to evaluate HDL-C-raising therapies in different clinical 
populations, as well as therapies targeted toward HDL flux 
and function rather than simply HDL-C elevation. Perhaps 
moving from a focus on the HDL-C hypothesis to a focus 
on the HDL flux hypothesis will permit a biologically 
based reassessment of the optimal therapeutic approach to 
targeting HDL for reduction in cardiovascular risk.
KeywORDS: reverse cholesterol transport, cholesterol 
efflux capacity, HDL dysfunction, HDL particle size, HDL 
lipidomics, HDL proteomics
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an effective strategy for the prevention of CVD events. 
These therapies have included niacin/niacin-lariproprant 
and CETP inhibitors.(1)
 Atherothrombosis Intervention in Metabolic 
Syndrome with Low HDL/High Triglycerides: Impact 
on Global Health Outcomes (AIM-HIGH) and The Heart 
Protection Study 2–Treatment of HDL to Reduce the 
Incidence of Vascular Events (HPS2-THRIVE) trials 
investigated the effect of niacin and niacin/laripoprant, 
respectively, in coronary heart disease (CHD) patients with 
low-density lipoprotein cholesterol (LDL-C) levels at the 
recommended target <70 mg/dL.(2,3) Elevations in HDL-C 
were not associated with fewer CVD events. Instead, there 
was harm from niacin treatment as shown by the increased 
risk of infections.(4) CETP inhibition with multiple agents 
(torcetrapib, dalcetrapib, and anacetrapib) has failed to 
reduce CVD events in high-risk patients treated with high-
intensity statin therapy.(5-7) The failure of torcetrapib was 
ascribed to torcetrapib-induced hypertensive effects via 
renin-angiotensinaldosterone activation and weak activity of 
dalcetrapib.(8,9) Early termination of the evacetrapib clinical 
trial in  Assessment of Clinical Effects of Cholesteryl Ester 
Transfer Protein Inhibition With Evacetrapib in Patients at 
a High-Risk for Vascular Outcomes (ACCELERATE) (7) 
was unexpected, not only based on the LDL-C-lowering 
efficacy of evacetrapib, but also in the increase in very small 
HDL particles and macrophage cholesterol efflux capacity.
(8) Based on event rates observed in statin-treated patients, 
early termination of ACCELERATE may not have allowed 
sufficient time to detect a treatment difference in CVD.
 HDLs comprise a multitude of discrete subpopulations 
that differ in composition, metabolism, cellular interactions, 
and functional properties.(10,11) Expansion of the core 
cholesterol in HDL particles interferes with apoA-I-
mediated cholesterol efflux via ABCA1 and alters the 
proteome and lipidome, resulting in species that are less 
effective in antioxidant and anti-inflammatory properties.
(12) Of the HDL functional assays, only macrophage 
cholesterol efflux has been validated in prospective studies.
(11,13-16) Efforts to solve the HDL puzzle require high 
throughput assays that accurately quantify discrete HDL 
species based on their protein and lipid components. HDL 
speciation may allow for the identification of specific HDL 
populations with functional or dysfunctional properties. 
The macrophage cholesterol efflux assay is an established 
method that has been used to characterize both functional 
and dysfunctional HDL.(13,14,17,18) Subsequent steps 
require evaluation of discrete HDL populations in the 
prediction of atherosclerosis and cardiovascular events.(19)
HDL-C Hypothesis
The most popular mechanistic hypothesis underlying 
the HDL-C hypothesis has been the concept of ‘reverse 
cholesterol transport’, namely that some component of 
the HDL system promotes cholesterol efflux from arterial 
macrophage foam cells and transports it to the liver for 
biliary excretion, leading to a reduction in lesion size 
(Figure 1).(20)
 However, recent events have raised serious questions 
about the validity of the HDL-C  hypothesis. Two clinical trials 
involving therapeutic elevations of HDL-C on individuals 
with low levels of LDL-C lowering were prematurely 
terminated on the basis of futility. The AIM-HIGH study 
was conducted with niacin, the most effective HDL-raising 
drug currently on the market; the Dalcetrapib in Patients 
with Recent Acute Coronary Syndrome (dal-OUTCOMES) 
study involved dalcetrapib, a drug in development that 
partially inhibits the CETP, which transfers cholesterol 
from HDL to very-low-density lipoprotein (VLDL) or 
LDL. Although many issues related to trial design are being 
actively debated, the hypothesis, based on epidemiological 
studies, that moderate HDL cholesterol raising would cause 
a marked reduction in events seems to have been refuted. 
Furthermore, a causal relationship of HDL-C with CHD has 
been challenged.(20)
 Maturation produces diverse HDL particles that vary in 
size, density, and lipid and protein composition. ApoA-I and 
apolipoprotein II account for 90% of HDL’s protein content, 
but close to 100 other HDL proteins have been described as 
HDL-associated.(21) Measuring HDL-C levels takes only 
the cholesterol mass into account, but cholesterol accounts 
for no more than 20% of a particular HDL particle, and its 
level may vary up to 10-fold, depending on a particle’s size.
(22) Thus, a confounder in interpreting HDL-C as a measure 
of circulating HDL concentration is the relative balance 
between large and small HDL particles.(23) HDL particle 
concentration, that provides information regarding the actual 
number of HDL particles in the circulation, can be measured 
by nuclear magnetic resonance (NMR) (24) or ion mobility 
analysis (25,26). Calibrated ion mobility analyses further 
demonstrate that precise measurements of small, medium, 
and large HDL particles can be obtained from plasma.(26) 
Therefore, evaluating changes in HDL subpopulations in 
response to therapy might be a better metric than HDL-C 
levels for predicting risk.(27)
 As well as varying in size, HDL particles vary in 
protein content, as HDL’s proteome is very rich. Alterations 
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Figure 1. Pathways influencing HDL cholesterol metabolism and flux and potential relationship to atherosclerosis.(20) (Adapted 
with permission from Springer). HSPC: hematopoietic stem and progenitor cell; LXR: liver X receptor; ABCG1: ATP-binding cassette 
sub-family G member 1; ABCA1: ATP binding cassette transporter A-1; ApoA-I: apolipoprotein A-I; HDL: high-density lipoprotein; LDL: 
low-density lipoprotein; VLDL: very low-density lipoprotein; LCAT: lecithin-cholesterol acyltransferase; CETP: cholesterylester transfer 
protein; SR-BI: scavenger receptor class B type I; LDLR: LDL-receptor; TG: triglyceride.
in protein cargo have been associated with pathological 
states, such as inflammation (28), poor response to therapy 
(29), autoimmune disease (30), and diabetes (31). Further 
improvements in quantitative techniques (32,33) and 
their application to clinical studies should identify panels 
of protein biomarkers that may be pharmacologically 
modifiable to reduce risk. Another important variable is 
HDL’s ability to promote cholesterol efflux from cultured 
macrophages with samples derived from serum, termed 
cholesterol efflux capacity (CEC). Cholesterol efflux 
capacity  has  been  a  stronger  predictor  of  prevalent  and 
incident coronary artery disease than HDL-C in multiple 
clinical trials.(13,14,24) In vitro assays of CEC of HDL 
may include four possible pathways: aqueous diffusion, 
scavenger receptor class B type I (SR-B1) receptor, and ATP 
binding cassette transporter A-1 (ABCA1), and ATP-binding 
cassette sub-family G member 1 (ABCG1) transporters.(27)
 Genetic epidemiology does not support a causal 
relationship between HDL cholesterol and future risk of 
myocardial infarction. In a Mendelian randomization study 
that included 20 studies (12,482 myocardial infarction cases 
and 95,407 controls), single nucleotide polymorphisms in 
the endothelial lipase gene (LIPG Asn396Ser) had higher 
HDL-C levels and similar nonlipid and other lipid risk factors 
for myocardial infarction.(34,35) Neither physiological 
function nor pathological dysfunction is recorded by the 
measurement of HDL-C. Novel biomarkers are currently 
searched and validated in clinical or epidemiological 
studies toward their potential to aid in drug development 
and improve risk prediction and monitoring of treatment 
response. Candidate biomarkers include HDL particle 
numbers, serum amyloid A, apolipoprotein (apo)C-III, 
sphingosine-1-phosphate (S1P), certain post-translational 
modifications of apoA-I, and cholesterol efflux capacity.(36) 
It is important  that future studies  take into  consideration 
the role of HDL function in addition to the level when the 
association of HDL with risk of cardiovascular disease and 
outcomes. This is especially true in patients with a high 
burden of oxidative stress and inflammation.(37)
HDL Particle Size, Lipidomics and Proteomics
Despite the spectacular collapse of the HDL-C hypothesis 
and the paucity of alternative strategies in the clinical space, 
the field as a whole has experienced a groundbreaking shift 
in the understanding of the basic biology and metabolism 
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of HDL. Advances have been made in the areas of HDL 
functionality as it relates to particle heterogeneity, 
biogenesis, and variations in lipid and protein cargo.
(38) The plasma concentration of HDL particles and their 
size distribution can be reliably measured using different 
approaches to identify subspecies with unique functional 
and compositional profiles. Currently, there is no consensus 
on the relative value of the different methods and on the 
number, concentration, functional status, and predictive 
power of the different HDL subparticles.
 HDL particles are highly heterogeneous in structure, 
composition, metabolism, and function. Distinct HDL 
subpopulations might, therefore, exert differential effects 
on  atherosclerosis.(39)  As  a  consequence,  plasma 
concentrations of specific HDL subpopulations can 
be hypothesized to reveal stronger associations with 
cardiovascular risk as compared to total HDL particle 
number. NMR measurements allow distinguish between 
large (size 9.4–14.0 nm), medium (8.3–9.3 nm), and 
small (7.3–8.2 nm) HDL particles.(24) Among these HDL 
subpopulations, levels of large HDL frequently display 
inverse relationships with cardiovascular risk in univariate 
analyses, whereas concentrations of small HDL particles 
typically reveal positive correlations with the risk.(40-50) 
Circulating concentrations of large and small HDL particles 
as well as those of large HDL particles and total LDL particles 
as measured by NMR are, however, known to be negatively 
correlated.(51) Available data reveal that diminished HDL 
particle number can be superior to reduced HDL-C levels 
in terms of cardiovascular risk prediction. Measurements of 
circulating concentrations of HDL particles can, therefore, 
be useful to improve clinical assessment of cardiovascular 
risk. This approach can also contribute to the evaluation 
of novel HDL-targeted therapies, which include CETP 
inhibitors, peroxisome proliferator-activated receptor 
(PPAR) activators, and reconstituted HDL.(51)
 HDL can be fractionated by different techniques 
into discrete  subclasses  according  to  physicochemical 
properties and chemical composition. Sequential 
ultracentrifugation allows separation of HDL into two main 
subfractions on the basis of density: large, light, lipid-rich 
HDL2 (d 1.063–1.125 g/mL) and small, dense, protein-rich 
HDL3 (d 1.125–1.21 g/mL).(10) HDL2 and HDL3 can be 
further subfractionated on nondenaturing polyacrylamide 
gradient gel electrophoresis into five distinct subpopulations 
of decreasing size: HDL2b, HDL2a, HDL3a, HDL3b, and 
HDL3c (10); equivalent subpopulations of increasing 
density can be quantitatively isolated using isopycnic 
density gradient ultracentrifugation (10). Such heterogeneity 
of HDL particles directly reflects differences in the relative 
content of proteins and lipids in HDL.(52)
 HDLs are a class of heterogeneous lipoproteins; 
their heterogeneity is attributable to a different content 
of apolipoproteins, lipids and enzymes and to the 
remodeling of  HDL  particles by lipolytic enzymes, lipid 
transporters and by lipid and apolipoprotein exchange 
with other circulating lipoproteins and tissues. Different 
HDL  subpopulations carry distinct and specific proteins 
or lipids, suggesting distinct and characteristic functions.
(39) HDL can be classified on the basis of density, resulting 
in the large buoyant HDL2 and the small dense HDL3, 
which can be further subfractionated into 5 distinct sub- 
populations (HDL2b, HDL2a, HDL3a, HDL3b and HDL3). 
Alternatively, HDLs can be separated on the basis of their 
electrophoretic mobility in pre-β- particles, α-particles and 
pre-α-particles. HDLs can also be classified according to 
their main apolipoprotein content into particles containing 
only apolipoprotein A-I (apoA-I, LpA-I) or both apoA-I and 
apoA-II (LpA- I/A-II) (Table 1).(39,53)
 The heterogeneity of HDLs is also reflected in their 
functions, since different subpopulations play distinct 
roles. HDLs possess several antiatherogenic functions. The 
best characterized activity of HDL is reverse cholesterol 
transport, the process by which excess cholesterol is 
transported from the peripheral tissues to the liver for 
excretion. Different HDL subpopulations interact with 
different cellular receptors to remove excess cholesterol 
from cells. Besides, HDLs, and in particular small dense 
HDL3, exert antiinflammatory and antioxidant activities. 
HDLs have a protective effect on vascular endothelium, 
are antithrombotic and antiinfectious and play a role in the 
modulation of immune responses and the control of glucose 
homeostasis.(39,54,55)
 The protein constituents of HDL in particular have 
been heavily dissected in recent years, primarily through 
liquid chromatography mass spectrometry (LC-MS), 
revealing several more proteins additional to the classical 
apolipoproteins, such as apoA-I, apoA-II, apoE and 
apoC-III, whose biological activities are diverse, but still 
encompass the role for HDL as antiatherogenic particle. 
Moreover, LC-MS technology has extended well beyond a 
tool for identification. Changes in apolipoprotein abundance 
can now be readily assessed using one or more of a 
number of strategies including label-free and label-based 
strategies.(56,57). Quantitative proteomics provides several 
innovative workflows that are poised to address many of 
the unknowns of apolipoprotein function and metabolism. 
Global proteomics studies have demonstrated that the HDL 
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Characteristic HDL-Subclasses
Shape Discoidal, Spherical
Density (untracentrifugation) HDL 2, HDL 3
Size (non denaturing gel 
electrophoresis)
HDL 2a, HDL 2b, HDL 3a, HDL 3b, HDL 
3c
Pre-β-article:
Pre-β1 (HDL3, LpA-I), Pre-β2 (LpA-
I, Pre-β3 (LpA-I), Pre-β4 (LpA-I) 
α-Particles:
Very small discoidal α-4 (HDL3, LpA-I), 
Small spherical α3 (HDL3, LpA-I:A-II), 
Medium spherical α2 (HDL3, LpA-I:A-II), 
Large spherical α1 (HDL2, LpA-I)
Pre-α particles: 
Pre-α1 (LpA-I), Pre-α2 (LpA-I), Pre-α3 
(LpA-I), Pre-α4 (LpA-I) 
LpA-I (prominent components of both 
HDL2 and HDL3):
Large LpA-I, Medium LpA-I, Small LpA-I 
LpA-I:
A-II (most found in HDL3) 
Charge (2-dimensional 
electrophoresis)
Composition 
(immunoaffinity) 
Table 1. HDL subclasses and major components of the HDL 
lipidome(52,53) (Adapted with permission from Karger AG, 
American Society for Biochemistry and Molecular Biology).
HDL Content
(% of total HDL Lipid)
35-50
Phosphatidylcholine 33-45
Lysophosphatidylcholine 0.5-5
Phosphatidylethanolamine 0.5-1.5
Phosphatidylinositol 0.5-1.5
Plasmalogens 0.5-1.5
Phosphatidylserine 0.02-0.04
Phosphatidylglycerol ND
Phosphatidic acid ND
Cardiolipin 0.2
5-10
Sphingomyelin 5-10
Ceramide 0.05
S1P 0.01-0.02
Sphingosylphosphorylcholine 0.0005
5-10
5-12
30-40Cholesteryl ester
Lipid Class
Phospholipids
Sphingolipids
Steroids
Triacylglycerides
proteome comprises between 90 and 100 proteins. The 
HDL proteome is differentially distributed across the HDL 
size fractions giving rise to a heterogeneous population 
of HDL particles.(58) In addition to proteins consistent 
with traditionally accepted roles in lipid transport, HDL 
carries surprising constituents, such as members of the 
complement pathway, protease inhibitors involved in 
hemostasis, acute-phase response proteins, immune 
function mediators, and even metal-binding proteins. This 
compositional diversity fits well with hundreds of studies 
demonstrating a wide functional pleiotrophy, including 
roles in lipid transport, oxidation, inflammation, hemostasis, 
and immunity.(21) Figure 2A shows the frequency of 
detection of HDL-associated proteins in some MS-based 
proteomic studies, meanwhile Figure 2B shows general 
functional relationships of HDL proteins. Establishing 
direct relationships between distinct HDL structure and 
composition on the one hand and specific atheroprotective 
functions on the other requires further study (Table 1). 
Such structure-function analysis of HDL particles bears the 
potential to identify clinically relevant, atheroprotective 
HDL subpopulations. Furthermore, development of HDL-
based therapies specifically designed to target beneficial 
subspecies of the circulating HDL pool can be facilitated 
using this approach. HDL lipidomics can equally contribute 
to the identification of biomarkers of both normal and 
deficient HDL functionality, which may in turn prove useful 
as biomarkers of cardiovascular risk. It remains to be shown 
whether such novel HDL-based lipidomic biomarkers can 
be superior relative to HDL-C levels.(52)
 Lipid-poor and small HDL displayed both high 
capacity for ABCA1-mediated cholesterol efflux and strong 
anti-inflammatory action, whereas the larger particles 
showed stronger antioxidant function. This study provides 
a novel perspective because it suggests that subspecies 
of HDL may be involved in different functions, and thus, 
the right mix of multiple HDL particle sizes may be most 
desirable to maximize cardioprotective benefits (Figure 3). 
Most importantly, the study offers an approach to generate 
these particles in vivo.(38)
 The HDL mass is equally distributed between lipid 
and protein cargo. The HDL lipidome is composed mainly 
of phospholipids, cholesteryl esters, triglycerides, and free 
cholesterol, for a total of over 200 individual lipid species 
in normolipidemic subjects. Some lipid components, such 
as phospholipids, sphingomyelin, and free cholesterol, have 
already been investigated as modulators of HDL functions, 
such as sterol efflux, vasodilation, and control of oxidation 
and inflammation.(52)
Regulation of HDL Metabolism
Understanding of the regulation of HDL metabolism has 
increased significantly in recent years, although these 
advances have not, to date, translated into the development 
of HDL-raising therapies that decrease cardiovascular 
morbidity and mortality. Given the high economic cost and 
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B
Figure 2. Relationship of HDL proteins. A: General functional relationships of the HDL proteins; B: Frequency of detection of HDL-
associated proteins in MS-based proteomic studies.(21) (Adapted with permission from American Society for Biochemistry and Molecular 
Biology).
A
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Figure 3. Overview of the regulation and 
interaction of traditional and novel high-
density lipoprotein (HDL) measures.(38) 
(Adapted with permission from American 
Heart Association).
 Most types of cells in the body do not express the 
capability of catabolizing cholesterol, so cholesterol efflux 
is essential for homeostasis. For instance, macrophages 
possess four pathways for exporting free (unesterified) 
cholesterol to extracellular HDL. The passive processes 
include simple diffusion via the aqueous phase and 
facilitated diffusion mediated by SR-BI. Active pathways 
are mediated by ABCA1 and ABCG1, which are membrane 
lipid translocases. The efflux of cellular phospholipid and 
free cholesterol to apoA-I promoted by ABCA1 is essential 
for HDL biogenesis.(68) 
 Recently, S1P, a lipid mediator that acts via G-protein-
coupled receptors, has featured prominently in HDL 
biology. The ability of HDL to protect the endothelium (69), 
myocardial ischemic injury and vasodilate (70) depends on 
the S1P cargo. HDL-bound apolipoprotein M binds, carries, 
and promotes receptor activation in a physiologically 
relevant manner.(71) 
 In addition, HDL-bound S1P seems to be distinct 
from albumin-bound S1P in the inhibition of endothelial 
inflammatory processes (72), barrier function (73) and 
lymphopoiesis (74), suggesting that chaperone- bound 
S1P acts as a biased agonist to evoke specific biological 
processes.  These  observations  suggest a  major function 
of  S1P  in  the  cardiovascular  protection  mediated  by 
HDL.(75,76)
increasing burden of CVD worldwide, there is a compelling 
need to identify strategies and  to develop therapeutic agents 
that can begin to resolve these issues.(59) The heterogeneity 
is a consequence of the continual remodeling and 
interconversion of HDL subpopulations by multiple plasma 
factors. Evidence that the remodeling of HDLs may impact 
on their cardioprotective properties is beginning to emerge. 
This serves to highlight the importance of understanding 
not only how the remodeling and interconversion of HDL 
subpopulations is regulated but also how these processes are 
affected by agents that increase HDL levels.(59)
 The 4 main apolipoproteins in human HDLs, in order 
of decreasing abundance, are apoA-I, apoA-II, apoA-IV, 
and apoE (Figure 4). ApoA-I is synthesized in the liver 
and intestine. Hepatic apoA-I is initially generated as a 
preproprotein that is cleaved intracellularly by a signal 
peptidase.(60) The resulting propeptide is secreted before 
cleavage by bone morphogenic protein-1 in a process that is 
facilitated by procollagen C-proteinase enhancer-2.(61,62) 
In vitro studies have found that ≤45% of apoA-I is lipidated 
before it is secreted from hepatocytes.(63-65) The initial 
lipidation of apoA-I occurs in the endoplasmic reticulum 
and is independent of the ABCA1.(63) Additional lipidation 
of apoA-I takes place in the golgi and at the plasma 
membrane in processes that are dependent on a dimeric 
form of ABCA1.(66,67)
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A
Figure 4. The biogenesis of many 
kind of lipoproteins. A: Biogenesis of 
apolipoprotein A-I (apoA-I)–containing 
discoidal high-density lipoproteins 
(HDLs); B: Biogenesis of spherical 
high-density lipoproteins (HDLs); C: 
Remodeling of apolipoprotein E (apoE)–
containing high-density lipoproteins 
(HDLs) by phospholipid transfer protein 
(PLTP).(59) (Adapted with permission 
from American Heart Association). 
B
C
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 There are 3 different transmembrane transporters along 
the apical membrane of the hepatocyte that actively promotes 
this process: the heterodimer ABCG5/ABCG8 (which 
facilitates cholesterol efflux), ABCB11 and the phospholipid 
pump, ABCB4.(78) Moreover, another transporter, ATP8B1, 
is also necessary for correct secretion of bile. ATP8B1 
moves phosphatidylserine in the opposite direction to the 
transport of phosphatidylcholine by ABCB4 to maintain the 
asymmetry of phospholipids required for proper membrane 
function.(78,79) Because cholesterol cannot be degraded in 
the cell, reverse cholesterol transport (RCT) is an essential 
process to ensure that cholesterol levels are balanced within 
the body. Work over the past years has identified miRNAs 
as important regulators of HDL-C metabolism. miRNAs 
control most of the steps of RCT including HDL biogenesis, 
cellular cholesterol efflux, hepatic HDL-C uptake, and bile 
acid synthesis and secretion.(80) In addition to their role 
in regulating HDL-C metabolism, HDL-enriched miRNAs 
regulate gene expression in recipient cells, thus providing 
an exciting novel mechanism that could explain a part of the 
antiatherogenic effect of HDL (Figure 5).(81,82) 
 Recent studies have highlighted the close partnership 
between activation of ecto-F1-ATPase by HDL or their 
major protein, apoA-I, and P2Y receptor signaling. For 
instance, on hepatocytes the HDL-apoA-I/ecto-F1-ATPase/
P2Y13 sequence contributes to HDL uptake and would 
be atheroprotective.(83-88) On adipocytes, HDL-apoA-I, 
ecto-F1-ATPase and P2Y signaling are all involved in lipid 
metabolism.(89-91) On endothelial cells, ecto- F1-ATPase 
is also activated by HDL-apoA-I and is potentially coupled 
to P2Y1 or P2Y12 receptors, promoting cell survival and 
HDL transcytosis.(92,93) In addition, HDL-apoA-I receptor 
signalling and P2Y receptor signaling share other common 
features on endothelium protection, such as the regulation 
of NO production and of pro-inflammatory cell adhesion 
molecules.(94-96) In many instances, these roles seem to 
rely on the enzymatic ATP hydrolase activity of ecto-F1-
ATPase, which generates extracellular ADP. Thus, it is 
tempting to propose a common framework that would 
involve the sequential activation of ecto-F1-ATPase by 
HDL- apoA-I, modulation of the extracellular ATP/ADP 
ratio and of downstream activation/inactivation of P2Y-
mediated signalling pathways.(97)
 As described, the metabolism of the HDL particle 
is a multistep process involving several apolipoproteins, 
enzymes, and transporters; therefore, genetic variation 
in genes regulating each of these steps will greatly affect 
HDL-C concentrations.(98) Mendelian disorders of high 
and low HDL-C levels have provided clues about the 
biology of HDL.(99) Candidate gene studies have identified 
Mendelian causes of low HDL-C levels, including 
mutations in ABCA1, APOA1, and lecithin-cholesterol 
acyltransferase (LCAT). Conversely, mutations in CETP 
and endothelial lipase (LIPG) result in high HDL-C levels.
(100) Our microbiota has been linked to intestinal health, 
immune function, bioactivation of nutrients and vitamins, 
and recently, complex disease phenotypes, such as obesity 
and insulin resistance.(101) Interestingly, recent studies 
showed that intestinal microbial processing of dietary 
choline to trimethylamine, which is further metabolized 
to trimethylamineoxide by flavin monoxygenases in 
human and rodent livers, was significantly correlated with 
Figure 5. Micro-RNA (miRNA) 
regulation of high-density lipoprotein 
(HDL) metabolism and reverse 
cholesterol transport.(82) (Adapted 
with permission from American Heart 
Association).
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CVD.(102,103) Furthermore, previous study found that 
trimethylamineoxide suppressed RCT via an intestinal 
microbiota-dependent mechanism in vivo.(104) These 
findings suggest a new concept that specific combinations 
of intestinal microbiota and host genetics may provide 
cardiometabolic regulation.(105)showed that intestinal 
microbial processing of dietary choline to trimethylamine, 
which is further metabolized to trimethylamineoxide by 
flavin monoxygenases in human and rodent livers, was 
significantly correlated with CVD.(102,103) Furthermore, 
previous study found that trimethylamineoxide suppressed 
RCT via an intestinal microbiota-dependent mechanism in 
vivo.(104) These findings suggest a new concept that specific 
combinations of intestinal microbiota and host genetics may 
provide cardiometabolic regulation.(105)
Functional and Dysfuctional HDL
HDL-C has direct effects on numerous cell types that influence 
CVD and metabolic health. These include endothelial 
cells, vascular smooth-muscle cells, leukocytes, platelets, 
adipocytes, skeletal muscle myocytes, and pancreatic cells. 
The effects of HDL or apoA-I, its major apolipoprotein, 
occur through the modulation of intracellular calcium, 
oxygen-derived free-radical production, numerous kinases, 
and enzymes, including endothelial nitric-oxide synthase 
(eNOS). ApoA-I and HDL also influence gene expression, 
particularly genes encoding mediators of inflammation in 
vascular cells.(106) There are several well-documented 
HDL functions such as RCT, inhibition of inflammation, 
or inhibition of platelet activation that may account for the 
atheroprotective effects of this lipoprotein. Mechanistically, 
these functions are carried out by a direct interaction of HDL 
particle or its components with receptors localized on the 
cell surface followed by generation of intracellular signals. 
Several HDL-associated receptor ligands such as apoA-I or 
S1P have been identified in addition to HDL holoparticles, 
which interact with surface receptors such as ABCA1; S1P 
receptor types 1, 2, and 3 (S1P1, S1P2, and S1P3); or SR-BI 
and activate intracellular signaling cascades encompassing 
kinases, phospholipases, trimeric and small G-proteins, and 
cytoskeletal proteins such as actin or junctional protein such 
as connexin. In addition, depletion of plasma cell cholesterol 
mediated by ABCA1, ABCG1, or SR-BI was demonstrated 
to indirectly inhibit signaling over proinflammatory or 
proliferation-stimulating receptors such as Toll-like or 
growth factor receptors.(107)
 Several well-documented functions of HDLs and 
apoA-I have the potential to protect against cardiovascular 
disease. The most extensively studied of these relates to 
the ability of HDLs to promote efflux of cholesterol from 
macrophages in the artery wall.(108) HDLs also inhibit 
vascular inflammation (109,110) and has antioxidant (109) 
and antithrombotic properties (95). They enhance endothelial 
function (111), promote endothelial repair (112,114), 
increase agiogenesis (114), suppress the production and 
mobilization of monocytes and neutrophils from bone 
marrow (115), and have recently been reported to have 
antidiabetic properties (55,116). It has been hypothesized 
that paraoxonase/arylesterase 1 (PON1) located on HDL 
possesses the capacity to hydrolyze lipid hydroperoxides 
and is largely responsible for the antioxidant effect of HDL. 
Transgenic animal evidence and clinical epidemiology 
strongly support an antiatherogenic role for PON1.
 Direct in vitro evidence for the PON1 antioxidant 
hypothesis has proved controversial, and other HDL 
components have been proposed to account for the 
antioxidant capacity of HDL, such as apoAI and apoM. 
These and other HDL components may interact with PON1 
to produce its antioxidant effects. The environment provided 
for this interaction by HDL may be critical.(117) The 
increasing evidence that HDL not only augments hypoxia-
mediated angiogenesis but also inhibits inflammatory driven 
neovascularization. This suggests that the regulation of 
angiogenesis by HDL is dependent on the pathophysiological 
context. One previous example of this was demonstrated 
in a study using the apoA-I mimetic peptide, D-4F. This 
peptide significantly increased the vascular expression 
and activity of haeme oxygenase-1 (HO-1).(118) HO-1 is 
induced by hypoxia to facilitate angiogenesis in response to 
ischaemia, but conversely also inhibits leucocyte infiltration 
by suppressing cytokine expression and consequently 
reduces inflammation-mediated neovascularization.(119) 
Studies recently confirmed these observations by directly 
comparing the effects of apoA-I/rHDL on angiogenesis 
in both hypoxic/ischaemic and inflammatory conditions. 
Mechanistically, the key to the conditional regulation of 
angiogenesis by HDL may be vascular endothelial growth 
factor (VEGF). VEGF uniquely contains both HIF-1α and 
NF-κB response elements in its promoter region and is 
therefore stimulated under both hypoxic and inflammatory 
conditions. HDL stabilizes hypoxia-inducible factor 
(HIF)-1α in hypoxia via modulation of its post-translation 
regulation, and in inflammation has striking inhibitory 
effects on each stage of the NF-κB activation pathway.(120)
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 The antithrombotic properties of native HDL are also 
related to the suppression of the coagulation cascade and 
stimulation of clot fibrinolysis. Furthermore, HDL stimulates 
the endothelial production of nitric oxide and prostacyclin, 
which are potent inhibitors of platelet activation. Thus, 
HDL’s antithrombotic actions are multiple and therefore, 
raising HDL may be an important therapeutic strategy to 
reduce the risk of arterial and venous thrombosis.(121) 
There is now convincing evidence that HDL modulates 
glucose metabolism in multiple tissues. These actions 
have deepened our understanding of the pathophysiology 
of a variety of disease states associated with low or 
dysfunctional HDL. While there are still many unanswered 
questions relating to the underlying mechanisms and key 
HDL component(s) responsible for the metabolic effects, 
this opens up the possibility of targeting glucose metabolism 
with HDL therapeutics currently in development. Future 
preclinical investigations and clinical trials will determine 
the relevance of HDL-mediated modulation of glucose 
metabolism to both glycemic control as well as tissue 
glucose supply to vital organs including the heart and the 
brain, especially under ischemic conditions.(122)
 HDLs and the main HDL apolipoprotein, 
apolipoprotein (apo)A-I, increase insulin synthesis and 
secretion in pancreatic b-cells. HDL apolipoproteins 
increase insulin synthesis and secretion in pancreatic b-cells 
by a mechanism similar to that of the intestinally derived, 
endogenous incretins, glucose-dependent insulinotropic 
peptide (GLP-1) and gastric inhibitory polypeptide (GIP).
(123)  Systemic  and  vascular  inflammation  has  been 
proposed to convert HDL to a dysfunctional form that has 
impaired anti-atherogenic effects.  A loss of anti-inflammatory 
and antioxidative proteins, perhaps in combination with 
a gain of proinflammatory proteins, might be another 
important component in rendering HDL dysfunctional. The 
proinflammatory enzyme myeloperoxidase induces both 
oxidative modification and nitrosylation of specific residues 
on plasma and arterial apoA-I to render HDL dysfunctional, 
which results in impaired ABCA1 macrophage transport, 
the activation of inflammatory pathways, and an increased 
risk of CAD.(16) Figure 6 shows the acute-phase of HDL.
 The development of monoclonal antibodies that 
identify specific forms of dysfunctional apoA-I is a promising 
area of investigation for monitoring pathophysiological 
Figure 6. Acute-phase HDL. HDL undergoes substantial modification during an acute-phase response.(16) (Adapted with permission 
from Springer).
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The Changing Face of HDL and The Best Way to Measure It
It is now well established from large-scale epidemiologic 
studies that increased plasma levels of HDL-C and LDL-C 
are associated with decreased and increased cardiovascular 
risk, respectively.(124) Consequently, HDL-C and LDL-C 
are routinely used as serum biomarkers for assessing an 
individual’s cardiovascular disease (CVD) risk.(125) Recent 
studies have questioned whether HDL-C is only a biomarker 
and is not mechanistically linked to cardiovascular 
protection.(126) While a central focus has been placed on 
the role of HDL in the RCT process, our appreciation for 
the other cardioprotective properties of HDL continues to 
expand with further investigation into the structure and 
function of HDL and its specific subfractions. Development 
of novel assays is empowering the research community to 
assess different aspects of HDL function, which at some 
point may evolve into new diagnostic tests.(127)
 The generation of different HDL subfractions 
throughout the RCT pathway is demonstrative of the size, 
compositional, and functional diversity of HDL. In addition 
to altering the size of the HDL subfractions, integration of 
cholesteryl esters and triglycerides fundamentally impacts 
the cardioprotective properties of HDL.(53,128) Further, 
the makeup of HDL subfractions is dynamic, as different 
lipolytic enzymes, lipid transporters, and apolipoprotein 
exchange mechanisms (with adjacent circulating 
lipoproteins and tissues) contribute to the formation and 
remodeling of HDL subfractions.(65) This also illustrates 
how simply measuring plasma HDL-C concentrations may 
not fully capture the impact of HDL on cholesterol flux 
between tissues, or its larger effect on CVD.
 A common methodology for assessing the 
antiatherogenic functionality of HDL is measuring CEC, or 
the ability of HDL to initiate the RCT pathway by accepting 
cholesterol from lipid-laden macrophages.(34,129) The 
methodology for determining CEC, first validated in a large 
clinical trial by Khera, et al., involves quantification of total 
cholesterol efflux from macrophages with apoB-depleted 
processes within the arterial wall and plasma, and for the 
evaluation of HDL/apoA-I therapies that are directed at 
mitigating the proatherogenic effects of dysfunctional HDL. 
As further research expands our knowledge in this arena, 
testing of HDL function could allow for better clinical risk 
stratification, optimization of individual clinical treatments, 
and the evaluation of novel therapeutics.(16) 
serum, and demonstrated CEC as a strong inverse predictor 
of coronary artery disease status independent of HDL-C 
concentration.(34) CEC quantified with macrophages in 
vitro is a much better predictor of prevalent CVD than is 
HDL-C.(34,130) In 2 different cohorts, cholesterol efflux 
capacity strongly and negatively associated with CVD 
status.(34) This relationship remained highly significant 
after correction for HDL-C. HDL-C accounted for only 34% 
of the variance in efflux capacity, indicating that HDL-C 
is not a major determinant of cholesterol efflux capacity.
(34,130)
 Two recent studies provided strong evidence that 
impaired CEC is also a strong predictor of incident CVD. 
In the Dallas Heart Study, impaired efflux capacity was 
the strongest predictor of future CVD events in a large 
cohort of multiethnic healthy subjects.(13) Similar results 
were reported in the European Prospective Investigation 
of Cancer (EPIC)-Norfolk study.(14) In both studies, 
impaired CEC remained a strong predictor of future events 
after adjusting for other risk factors, including HDL-C 
and LDL-C, suggesting that this metric provides clinically 
valuable information that is independent of traditional 
lipid risk factors.(131) Given the disappointment so far in 
developing new HDL-C-targeted drugs for treatment of 
CVD, there has been great interest in determining whether 
another HDL metric may better capture its potential 
antiatherogenic effects. A functional assay assessing HDL-
promoted cholesterol efflux has garnered interest, and may 
be a convenient way to assess HDL function in RCT. In this 
section, we also discuss other potential functions of HDL 
and novel qualitative and quantitative assays. HDL is known 
to bind over 80 different types of proteins and transports 
more than 100 different species of lipids, so it likely has 
other functions outside RCT.(132,133) Finally, the function 
of HDL is highly associated with its com-osition, so we 
also discuss methodologies for identifying HDL-associated 
proteins, lipids, and physical properties.
 There is also good evidence that the concentration of 
HDL, HDL particle number (HDL-P), provides clinically 
useful information that is distinct from HDL-C. Two 
methods, NMR spectroscopy (134) and ion mobility (IM) 
(135), have been used to quantify HDL-P. However, these 
methods give different estimates of HDL-P concentration 
and size.(134,135) In future studies, it will be critical for 
investigators to validate the quantification of HDL-P by 
NMR and ion mobility (IM). At present, NMR and IM 
are the only available methods for ascertaining HDL-P.
(10) In some recent studies, HDL-P concentration has 
emerged as a predictor of CVD risk that may be superior 
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to that of HDL-C in both population studies (136,137) and 
randomized, clinical trials of lipid-modifying therapies.
(46,138,139) In the Multi-Ethnic Study of Atherosclerosis 
(MESA), low HDL-P predicted higher risk of elevated 
carotid intima-medial thickness regardless of whether the 
baseline HDL-C level was high (≥55 mg/dL) or low (<42 
mg/dL).(137) In the Justification for the Use of Statins in 
Prevention: An Intervention Trial Evaluating Rosuvastatin 
(JUPITER), HDL-P was a better marker of residual risk in 
statin-treated patients than chemically measured HDL-C, 
apoA-I, or average HDL size.(139)
 Evaluation of antioxidant effects of HDL has 
encompassed several functional methods that evaluate 
the efficiency of HDL particles to protect LDL against 
oxidative modification. LDL lipid peroxidation by free 
radicals the presence of HDL proceeds in a 2-step process 
that involves a slow rate of conjugated diene accumulation 
ascribed to the presence of antioxidants including those 
in HDL and a second rapid phase that is principally 
dependent on the antioxidative functionality of HDL.
(15) An alternative method for evaluating the antioxidant 
effects of HDL is the cell-free assay. The cell-free assay 
or the HDL-oxidized 1-palmitoyl- 2-arachidonoyl-sn-
glycero-3-phosphorylcholine (OxPAPC) assay measures 
the ability of plasma HDL to reduce formation of oxidized 
phospholipids.(140-142) The addition of the  fluorochrome 
2’,7’-dichlorofluorescein produces a  fluorescent signal that 
depends on the concentration of OxPAPC in vitro.
 Some candidate biomarkers associated with metrics 
that reflect HDL functions have recently emerged. They 
fall into three categories: size and quantitative features 
such as HDL particles size and number (51,143), markers 
of HDL properties such as HDL-associated sphingosine-1-
phosphate that contributes to the cytoprotective activity of 
HDL and endothelial nitric oxide production (144-148) and 
markers of hepatobiliary RCT such as CEC, HDL turnover 
and hepatic HDL uptake (13,14,149) Among HDL cellular 
partners, the ecto-F1-ATPase is a receptor for apoA-I that 
contributes to several HDL atheroprotective properties, 
including cellular uptake of HDL and endothelial cell 
protection.(97) Thus, indicators of ecto-F1-ATPase activity 
might have the potential to cover several categories of HDL-
related biomarkers.(150)
 Circulating inhibitory factor 1 (IF1) is strongly and 
independently associated with mortality in coronary artery 
disease patients but, in the same population, HDL-C is not.
(151) According to our hypotheses, the IF1 level assesses 
metabolic and vascular HDL protective properties by 
reflecting the ecto-F1-ATPase/P2Y pathway activation by 
apoA-I, both in hepatic reverse cholesterol transport and 
vascular endothelium protection. In addition, serum IF1 
might also reflect myocardial function, which can explain 
its correlation with heart rate and left ventricular ejection 
fraction (LVEF). F1 thus joins other emerging biomarkers 
that have proven to be better than HDL-C level for evaluating 
cardiovascular risk and determining pharmacotherapy, such 
as HDL CEC or HDL particles number. IF1 can be used in a 
panel of biomarkers to better stratify cardiovascular risk and 
to set treatment. 
 The challenge is to develop laboratory assays that 
quantify the various HDL functions that may improve 
CVD risk assessment and augment the evaluation of HDL-
modifying therapies. Efforts to develop reproducible, cost-
effective, validated assays that measure the potentially 
protective functions of HDL are now recognized as a major 
challenge for the cardiovascular field. Currently, there is 
no consensus concerning the HDL functions that should be 
targeted, nor are there standardized assays to measure HDL 
function as a tool to improve either CVD risk assessment 
or the assessment of therapeutic interventions. Another 
challenge is to validate measurements of HDL particles 
to be able to standardize assays of function with HDL 
quantification.(15)
In population studies, HDL-C is inversely related to 
the risk of myocardial infarction and death.(152-155) 
Of note, in patients fully treated according to current 
guidelines with intense statin therapy and LDL-C at target 
levels, HDL-C remains predictive of outcome for major 
adverse cardiovascular events.(6) Unfortunately, it has 
been proven difficult to reduce coronary risk with drugs 
increasing HDL-C, such as  brates, niacin, or inhibitors 
of CETP, beyond that achieved with statin therapy alone.
(2,5,156,157) Moreover, in several inborn errors of human 
HDL metabolism and genetic mouse models with altered 
HDL metabolism, the changes in HDL-C levels were not 
associated with accompanying changes in cardiovascular 
risk or atherosclerotic plaque load, respectively, as has been 
expected from epidemiological studies.(35,158,159) Thus, 
the pathogenic role and, suitability of HDL as a therapeutic 
target has increasingly been questioned. In fact, it has 
been argued that low HDL-C may only represent a marker 
for proatherogenic risk factors, rather than HDL being a 
mediator protecting against atherogenesis (Figure 7).(160)
The Development Of Future HDL-Targeted Therapies
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Figure 7. Proposed direct vascular protective and potentially antiatherogenic effects of normal high-density lipoprotein (HDL).
(160) (Adapted with permission from American Heart Association).
 One argument to explain the HDL controversy is 
that HDL-C concentration is a poor measure for targeted 
intervention. HDL-C concentration is considered a surrogate 
for the efficiency of cholesterol efflux from tissues. 
However, given that macrophage-derived cholesterol 
represents only a minor proportion of the cholesterol 
transported by HDL particles, this may be an inadequate 
measure. Moreover, HDL-C concentration is a static 
measurement, and does not take into account the dynamics 
of the HDL particle population and HDL functionality, 
which might differ depending on the metabolic status of 
individuals. For instance, patients with type 2 diabetes 
display a higher catabolic rate of HDL-ApoA-I (148) and 
HDL from coronary patients does not have endothelial anti-
inflammatory effects (161), illustrating the need to identify 
more precisely the patient subgroups that should benefit 
from personalized HDL therapies.(162) Therefore, it will be 
important to demonstrate that novel drugs not only increase 
HDL-C plasma levels but also improve HDL function in 
patients at high cardiovascular risk.(163)
 Although RCT was first postulated to be a major 
contributor to the causative association between low plasma 
HDL-C and ischaemic heart disease, numerous other 
plausible contributing mechanisms have been uncovered. 
Animal models have been an important vehicle for these 
discoveries, with more recent investigations providing a 
clinical context for several antiatherothrombotic actions of 
HDL. These include antiplatelet (164,165), antioxidative 
(166), anti-inflammatory (167), anti-apoptotic (168,169) 
and vasodilatory (111,170,171) activities, as well as effects 
on glucose metabolism (55,172-174). These mechanisms 
have the potential to act at multiple stages throughout the 
development of atherothrombosis. Via these mechanisms, 
HDL-targeted therapies could both prevent the formation 
and reduce the progression of plaques by slowing the 
accumulation of cholesterol in the artery wall and also by 
stabilizing inflamed plaques that are vulnerable to rupture.
(175)
 Several strategies to therapeutically target the 
metabolism, particle structure and function of HDL are 
emerging. These include ApoA1-mimetic peptides, agonists 
of the liver X receptor (LXR), agonists of the farnesoid 
X receptor (FXR), inhibitors of LIPG, antagonists of 
microRNAs (miRNAs) and antisense oligonucleotides 
(ASOs) targeted to genes that are implicated in HDL 
metabolism, including the CETP and ApoC3 genes.(175) 
 HDL functions reflect the physiological role of the 
lipoprotein better than HDL-C quantity, the intake of olive 
oil phenolic compounds resulted in an improvement in CEC, 
HDL antioxidant defenses, HDL size distribution, and other 
characteristics related to HDL quality. Olive oil phenolic 
compounds bound to HDLs, or surrounding the lipoprotein, 
improve their oxidative/inflammatory status which may 
justify an increase in HDL functionality. Modifications in 
HDL composition because of the consumption of virgin 
olive oil (VOO) might also explain these changes. However, 
large-scale, randomized controlled trials with VOO-rich 
dietary interventions are required to definitively confirm 
the protective role of olive oil phenolic compounds in HDL 
biological functions.(176)
 Nevertheless, HDL has not yet been successfully 
exploited for therapy. One potential reason for this shortfall 
is the structural and functional complexity of HDL particles, 
which carry more than 80 different proteins and more 
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than 200 lipid species as well as several microRNAs and 
other potentially bioactive molecules. This physiological 
heterogeneity is further increased in several inflammatory 
conditions that increase cardiovascular risk, including 
coronary artery disease itself but also diabetes mellitus, 
chronic kidney disease, and rheumatic diseases. The 
quantitative and qualitative modifications of the proteome 
and lipidome, as well as the resulting loss of functions or gain 
of dysfunctions, are not recovered by the biomarker HDL-C. 
As yet the relative importance of the many physiological 
and pathological activities of normal and dysfunctional 
HDL, respectively, for the pathogenesis of atherosclerosis 
is unknown. The answer to this question, as well as detailed 
knowledge of structure-function-relationships of HDL-
associated molecules, is a prerequisite to exploit HDL for 
the development of anti-atherogenic drugs as well as of 
diagnostic biomarkers for the identification, personalized 
treatment stratification, and monitoring of patients at 
increased cardiovascular risk.(177)
Conclusion
The clinical utility of HDLs has been scrutinized upon the 
publication of Mendelian randomization studies showing 
no effect of HDL-C modifying variants on CVD outcome. 
The failures of randomized controlled HDL-C-directed 
intervention trials have further fueled this skepticism. This 
general criticism originates from oversimplification that 
has equated ‘HDL-C’ with ‘HDL’ and misconceived both 
as the ‘good cholesterol’. HDL particles are heterogeneous 
and carry hundreds of different lipids, proteins, and 
microRNAs. Many of them but not cholesterol, that is, 
HDL-C, contributes to the multiple protective functions 
of HDLs that probably evolved to manage potentially life-
threatening crises. Quantification of HDL particle numbers, 
distinct proteins or lipids, and modifications thereof as well 
as bioassays of HDL functionality are currently explored 
toward their diagnostic performance in risk prediction and 
monitoring of treatment response. Any successful clinical 
exploitation of HDLs will depend on the identification of the 
most relevant (dys)functions and their structural correlates. 
Stringent or prioritized structure-(dys)function relationships 
may provide biomarkers for better risk assessment and 
monitoring of treatment response. The most relevant 
agonists carried by either functional or dysfunctional HDLs 
as well as their cellular responders are interesting targets for 
drug development.
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60. Stoffel W, Krüger E, Deutzmann R. Cell-free translation of human 
liver apolipoprotein AI and AII mRNA. Processing of primary 
translation products. Hoppe Seylers Z Physiol Chem. 1983; 364: 
227-37. 
61. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 
(BMP-1) cleaves human proapolipoprotein A1 and regulates its 
activation for lipid binding. Biochemistry. 2007; 46: 8445-50. 
62. Zhu J, Gardner J, Pullinger CR, Kane JP, Thompson JF, Francone 
OL. Regulation of apoAI processing by procollagen C-proteinase 
enhancer-2 and bone morphogenetic protein-1. J Lipid Res. 2009; 
50: 1330-9. 
63. Gillard BK, Lin HY, Massey JB, Pownall HJ. Apolipoproteins A-I, 
A-II and E are independently distributed among intracellular and 
newly secreted HDL of human hepatoma cells. Biochim Biophys 
Acta. 2009; 1791: 1125-32. 
64. Kiss RS, McManus DC, Franklin V, Tan WL, McKenzie A, Chimini G, 
Marcel YL. The lipidation by hepatocytes of human apolipoprotein 
A-I occurs by both ABCA1-dependent and -independent pathways. 
J Biol Chem. 2003; 278: 10119-27. 
65. Ji A, Wroblewski JM, Cai L, de Beer MC, Webb NR, van der 
Westhuyzen DR. Nascent HDL formation in hepatocytes and role 
of ABCA1, ABCG1, and SR-BI. J Lipid Res. 2012; 53: 446-55. 
66. Maric J, Kiss RS, Franklin V, Marcel YL. Intracellular lipidation 
of newly synthesized apolipoprotein A-I in primary murine 
hepatocytes. J Biol Chem. 2005; 280: 39942-9. 
67. Nagata KO, Nakada C, Kasai RS, Kusumi A, Ueda K. ABCA1 
dimermonomer interconversion during HDL generation revealed 
by single- molecule imaging. Proc Natl Acad Sci USA. 2013; 110: 
5034-9. 
68. Phillips MV. Molecular mechanisms of cellular cholesterol efflux. J 
Biol Chem. 2014; 289: 24020-9. 
69. Kimura  T,  Sato  K,  Malchinkhuu  E,  Tomura  H,  Tamama  K, 
Kuwabara A, et al.  High-density  lipoprotein  stimulates endothelial 
cell  migration  and  survival  through  sphingosine  1-phosphate 
and its receptors.  Arterioscler  Thromb  Vasc  Biol.  2003;  23: 
1283-8. 
70. Nofer JR, van der Giet M, Tölle M, Wolinska I, von Wnuck Lipinski 
K, Baba HA, et al. HDL induces NO-dependent vasorelaxation via 
the lysophospholipid receptor S1P3. J Clin Invest. 2004; 113: 569-
81. 
71. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, 
Ahnström J, Sevvana M, et al. Endothelium-protective sphingosine-
1-phosphate provided by HDL- associated apolipoprotein M. Proc 
Natl Acad Sci USA. 2011; 108: 9613-8. 
72. Galvani S, Sanson M, Blaho VA, Swendeman SL, Obinata H, Conger 
H, et al. HDL-bound sphingosine 1-phosphate acts as a biased 
agonist for the endothelial cell receptor S1P1 to limit vascular 
inflammation. Sci Signal. 2015; 8: ra79. doi: 10.1126/scisignal.
aaa2581. 
73. Wilkerson BA, Grass GD, Wing SB, Argraves WS, Argraves KM. 
Sphingosine 1-phosphate (S1P) carrier-dependent regulation of 
endothelial barrier: high density lipoprotein (HDL)-S1P prolongs 
endothelial barrier enhancement as compared with albumin-S1P via 
effects on levels, traf cking, and signaling of S1P1. J Biol Chem. 
2012; 287: 44645-53. 
74. Blaho VA, Galvani S, Engelbrecht E, Liu C, Swendeman SL, Kono M, 
et al. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis 
and neuroinflammation. Nature. 2015; 523: 342-6. 
75. Levkau B. HDL-S1P: cardiovascular functions, disease-associated 
alterations, and therapeutic applications. Front Pharmacol. 2015; 6: 
243. doi: 10.3389/fphar.2015.00243. 
76. Galvani S, Hla T. Quality versus quantity. Arterioscler Thromb Vasc 
Biol. 2017; 37: 1018-9. 
77. Esteller A. Physiology of bile secretion. World J Gastroenterol. 2008; 
14: 5641-9. 
78. Paulusma CC, Folmer DE, Ho-Mok KS, de Waart DR, Hilarius PM, 
Verhoeven AJ, Oude Elferink RP. ATP8B1 requires an accessory 
protein for endoplasmic reticulum exit and plasma membrane lipid 
flippase activity. Hepatology. 2008; 47: 268-78. 
79. Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, Rudi 
de Waart D, et al. Atp8b1 deficiency in mice reduces resistance of 
the canalicular membrane to hydrophobic bile salts and impairs bile 
salt transport. Hepatology. 2006; 44: 195-204. 
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